Ozempic (semaglutide) is officially approved in Australia for the treatment of type 2 diabetes. It works by mimicking the GLP‑1 hormone, supporting blood sugar regulation, appetite control, and weight loss.
Patients with diabetes can receive a subsidised price of A$31.60 per pen (or A$7.70 for concession card holders) under the PBS, instead of the private cost of approximately A$140–200 per pen read more.
Wegovy, which also contains semaglutide but at a higher dose approved for obesity treatment, became available in Australia in August 2024. Unlike Ozempic, Wegovy is not PBS‑subsidised and costs around A$460 per dose .
Shortages and Black Market Risks
High demand has caused ongoing shortages of Ozempic in Australia, expected to continue through late 2025, according to the TGA read full source.
The Therapeutic Goods Administration warns against sourcing Ozempic from unauthorised providers or “black market” online suppliers. Such products may be counterfeit and pose significant health risks read more .
Off‑Label Use for Weight Loss
Many Australians are using Ozempic “off label” to lose weight. Although this use is legal, it is limited by supply and cost. Patients without diabetes may pay A$150 per pen wholesale, making it financially challenging read more.
GPs are being urged to prioritise Ozempic for people with diabetes due to shortages read more.
Insurance and Policy Context
Some private health insurers (including Bupa, Medibank, NIB) now offer coverage for GLP‑1 medications, reflecting growing acceptance of their use read more.
The Royal Australian College of General Practitioners and other health bodies support PBS subsidy expansion to include weight‑loss use, citing widespread medical needs and disease prevention read more. However, proposals to include Wegovy and Mounjaro on the PBS have been rejected so far read more.
International Price Comparison
Australia’s list price for Ozempic remains significantly lower than U.S. prices. A comparison study showed Australia’s monthly cost is about A$130 compared to almost US$936 in the U.S. read more
What This Means for Australians
- If you have type 2 diabetes and a valid prescription, Ozempic is available at a reduced PBS rate.
- If you’re using it for weight loss without diabetes, expect full private costs and limited pharmacy supply.
- Local shortages may require prioritisation by doctors and pharmacies, delaying new starts.
- Black market purchases are unsafe and discouraged by the TGA.
- Insurance coverage and PBS subsidy remain limited for weight‑loss usage, though policy debates continue.
Bottom Line
Ozempic remains an important and effective diabetes treatment in Australia with affordable subsidised pricing for eligible patients. Off‑label uses are growing but face financial and supply barriers. Ongoing shortages and a lack of subsidy for obesity use mean many Australians must pay privately or wait for availability.
If you are considering Ozempic, consult your doctor about eligibility, prescription access, and insurance alternatives. For information on higher-dose semaglutide options and lifestyle strategies, see Wegovy in Australia and What Is Ozempic?
Ava Sinclair
Ava Sinclairis a wellness expert and writer with a passion for integrative health, sustainable living, and everyday rituals that support long-term well-being. She brings a thoughtful, science-informed perspective to topics that connect body, mind, and lifestyle.
